Initiator Pharma A/S has received notice of approval for listing at AktieTorget

Initiator Pharma A/S (“Initiator Pharma”) announced today January 16, 2017, that the company has received notice of approval for listing at AktieTorget. In connection with the planned listing, Initiator Pharma also plans to conduct a rights issue totaling approximately SEK 20.5 million (before issuance costs). The listing at AktieTorget is subject to the lowest level in the rights issue, approximately SEK 14.9 million, being reached. The general public is also being provided the opportunity to subscribe for shares as a part of the new shares issue. The subscription period for the rights issue is planned to begin January 26, 2017 and planned to close February 9, 2017. At the commencement of the rights issue, the Company has received subscription commitments totaling approximately SEK 11.9 million, representing approximately 58 percent of the volume of the issuance of new shares. The new share issue is implemented with preferential rights for existing shareholders, whose preferential rights are exercised on the basis of subscription rights. Since the Company has not previously been listed, no organized trading in subscription rights or Paid Subscription Shares (BTAs) will take place. The Memorandum will be available on the websites of the Company (www.initiatorpharma.com), AktieTorget (www.aktietorget.se) and Sedermera Fondkommission (www.sedermera.se) at the latest in connection with the commencement of the  subscription period. In addition, the corresponding Danish prospectus for subscribers resident in Denmark will be available on the websites of the Company  (www.initiatorpharma.com) and Finanstilsynet, the Danish Financial Supervisory Authority  (www.finanstilsynet.dk).

About Initiator Pharma and the planned new share issue

Initiator Pharma is a Danish pharmaceutical company originally spun out from Saniona AB. The Company’s main focus is the pharmaceutical candidate IPED2015, which constitutes a new treatment for the indication of erectile dysfunction (ED) - the inability of a man to achieve and maintain an erection and thus be able to complete sexual intercourse. The Company intends to initiate comprehensive studies and continue with further development of IPED2015, and therefore plans to implement a rights issue in connection with its listing on AktieTorget. The reason for the rights issue is to finance the activities of the implementation of the first phases of these studies. The offer is scheduled to encompass up to 3,721,689 newly issued shares at a subscription price of SEK 5.50 per share, corresponding to approximately SEK 20.5 million.

The offer in brief

Planned subscription period:

26 January – 9 February 2017.

Subscription price/Issue price:

SEK 5.50 per share.

The scope of the Offer:

The offer encompasses a maximum of 3,721,689 shares, corresponding to approximately SEK 20,5 million. The approved lowest level of acceptance for implementation of the new share issue is approximately SEK 14.9 million, corresponding to SEK 2,700,000 shares.

Payment:

Cash settlement is to be made in late February 2017.

Number of shares before the new share issue:

4,962,254 shares.

Valuation (pre-money):

Approximately SEK 27.3 million.

Listing on AktieTorget:

The plans are for the company to be listed on AktieTorget. 16 March 2017 is the projected dated for the first day of trading.

ISIN code:

DK0060775872.

Subscription commitments: The Company has received subscription commitments totaling approximately SEK 11.9 million, representing approximately 58 percent of the issue volume.

Planned record day for the preference rights: The planned record date for obtaining subscription rights is 19 January 2017. The new share issue is implemented with preferential rights for existing shareholders, whose preferential rights are exercised on the basis of subscription rights. One (1) subscription right will be received for each existing share. Four (4) such subscription rights entitle the holder to subscribe to three (3) new shares.

Trading in subscription rights (TR) and paid subscription shares (BTA): Since the Company has not previously been listed, no organized trading in subscription rights or Paid Subscription Shares (BTAs) will take place.

Investor meetings

In connection with the process of issuing new shares, representatives of Initiator Pharma will participate in a number of investor meetings, in order to provide information about the Company's business activities and its plans for the future. See the schedule below for the Company’s road show.

The Memorandum, Danish Prospectus, application form and teaser

The Memorandum will be available on the websites of the Company (www.initiatorpharma.com), AktieTorget (www.aktietorget.se) and Sedermera Fondkommission (www.sedermera.se) at the latest in connection with the commencement of the of the subscription period. The teaser and application forms will be available via the above websites, no later than when the subscription period commences. In addition, the corresponding Danish prospectus for subscribers resident in Denmark will be available on the websites of the Company (www.initiatorpharma.com) and Finanstilsynet, the Danish Financial Supervisory Authority (www.finanstilsynet.dk).

Financial Advisor

Sedermera Fondkommission is the financial advisor to Initiator Pharma in connection with the new share issue and the listing on AktieTorget.

For more information about the planned new share issue and the listing on AktieTorget, please contact:

Sedermera Fondkommission

Telephone: +46 (0)40-615 14 10

E-mail: info@sedermera.se

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

This information is such information that Initiator Pharma is required to disclose under the EU Market Abuse Regulation. The information was provided under the above contact person’s auspices, for publication on 16 January 2017.

A few words about Initiator Pharma

Initiator Pharma is a pharmaceutical company based in Aarhus, Denmark, spun off from Saniona AB (listed on Nasdaq Stockholm First North Premier). The Company’s main focus is the pharmaceutical candidate IPED2015 which constitutes a new treatment for the indication of erectile dysfunction (ED), that is, the inability of a man to achieve and maintain an erection and thus be able to complete sexual intercourse. Initiator Pharma’s new treatment method with IPED2015 is intended to treat the large group of patients suffering from of erectile dysfunction who are resistant to current treatment methods.